We are a patient first and data driven regenerative medicine company. We strive to develop cures that better the lives of people living with chronic conditions.

About Us

iTolerance is a privately held regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging its proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL biotin-PEG microgelplatform technology), iTOL-100, iTolerance is advancing a pipeline of programs that have the potential to cure diseases. iTOL-101 utilizes allogeneic cadaveric pancreatic islet and is being developed as a potential cure for Type 1 diabetes. In a pre-clinical non-human primate study, utilizing the iTolerance platform technology, iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression was observed.  The Company’s lead commercial program, iTOL-102, is intended to combine iTOL-100 technology with an inexhaustible supply of insulin producing allogeneic stem cell-derived pancreatic islets and is being developed as a potential cure for Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-401 as a nanoparticle formulation for large organ transplant without the need for life-long immunosuppression.

Our Values